anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Plant defence against pathogens generally occurs at the expense of growth and yield. Uncoupling the inverse relationship between growth and defence is of great importance for crop breeding, while the underlying genes and regulatory mechanisms remain largely elusive. The exocytosis complex was shown to play an important role in the trafficking of receptor kinases (RKs) to the plasma membrane (PM). Here, we found a Cucumis sativus exocytosis subunit Exo70B (CsExo70B) regulates the abundance of both development and defence RKs at the PM to promote fruit elongation and disease resistance in cucumber. Knockout of CsExo70B resulted in shorter fruit and susceptibility to pathogens. Mechanistically, CsExo70B associates with the developmental RK CsERECTA, which promotes fruit longitudinal growth in cucumber, and contributes to its accumulation at the PM. On the other side, CsExo70B confers to the spectrum resistance to pathogens in cucumber via a similar regulatory module of defence RKs. Moreover, CsExo70B overexpression lines showed an increased fruit yield as well as disease resistance. Collectively, our work reveals a regulatory mechanism that CsExo70B promotes both fruit elongation and disease resistance by maintaining appropriate RK levels at the PM and thus provides a possible strategy for superior cucumber breeding with high yield and robust pathogen resistance.
Background: The narrower focal zone (FZ) size of modern lithotripter was considered as one of the factors that resulted in suboptimal treatment result of extracorporeal shockwave lithotripsy (SWL). Therefore, we investigate the efficacy and safety of standard narrow or extended (FZ) sizes in SWL for patients with renal stones. Materials and Methods: In this prospective study conducted between April 2018 and October 2022, patients with renal stones were randomized to receive SWL with either standard or extended FZ. Treatment was delivered using a Modulith SLX-F2 lithotripter with a maximum of 3000 shocks at 1.5 Hz. The primary outcome was treatment success 12 weeks after a single SWL session, defined as the absence of a stone or stone fragment <4 mm on computed tomography. Secondary outcomes included the incidence of perinephric hematoma, stone-free rate (SFR), and changes in the urinary levels of acute renal injury markers. Results: A total of 320 patients were recruited, and 276 patients were randomized into the two groups. The two groups had similar baseline parameters. The treatment success rate was significantly better for standard FZ (74.3%) than the extended FZ group (59.3%) (p = 0.009). Standard FZ also had a significantly better SFR (Grade-A, 36.8% vs 23.0%, p = 0.013) and less pain after treatment. Both groups had similar perinephric hematoma formation rates, unplanned hospital admission rates, and changes in urinary acute renal injury markers. Conclusions: The standard narrow FZ has better treatment efficacy and similar safety compared with the extended FZ during SWL for renal stones. This clinical trial has been registered in the public domain (CCRBCTR) under trial number CUHK_CCRB00510.
The method for the biophysical correction of the neurologic state of the children and adults with congenital or acquired defects of central nervous system is proposed. The respiration of the patient is provided in the sessions of biocontrolled normobaric hypoxic therapy in three or four stages depending on the initial sensitivity of the patient to the oxygen deficiency. At the first stage (10-15 minutes), the oxygen content in hypoxic gas mixture (HGM) is gradually reduced from 21 % to 15-12 % until the increase in pulse rate (PR) by 10-15 % over the initial value. At the second stage, the respiration with HGM continues for further 5-8 minutes until PR stabilization. At the third stage, the respiration with HGM continues for 10-15 minutes followed by further reduction of oxygen content to 10 % but not less than 9 % until PR stabilization. The fourth stage is used only for patients who are highly resistant to hypoxia. The fourth stage is initiated after the repeated PR stabilization at the maximally tolerated hypoxia level.
The present invention relates to a novel glial cell line-derived neurotrophic factor receptor beta (GDNFR-β) and novel glial cell line-derived neurotrophic factor receptor gamma 1 and 2 (GDNFR-ηl and GDNFR-η2). The receptors of the present invention share high homology with glial cell line-derived neurotrophic factor receptor alpha and have been named GDNFR-β, GDNFR-η1 and GDNFR-η2. More specifically, isolated nucleic acid molecules are provided encoding human GDNFR-β, GDNFR-η1 and GDNFR-η2 receptors. GDNFR-β, GDNFR-η1 and GDNFR-η2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of GDNFR-β, GDNFR-η1 and GDNFR-η2 activity. Also provided are diagnostic and therapeutic methods for disorders and diseases including Parkinson's disease, thyroid tumor, kidney failure and gut dysfunction.
The proposed therapy is called chronic tibial nerve stimulation (CTNS), which is a low-risk, minimally invasive chronic implant for the treatment of urgency urinary incontinence. CTNS works by the same mechanism as percutaneous tibial nerve stimulation (PTNS), but is provided for chronic use with an implantable device. CTNS treatment involves the placement of a minimally invasive stimulator with an embedded receiver at the tibial nerve. The Protect CTNS System has an external transmitter that activates the implanted stimulator and sends mild electrical pulses to the tibial nerve. These impulses travel to the sacral nerve plexus, the group of nerves at the base of the spine responsible for bladder function. Since stimulation with the Protect CTNS System is chronic it is expected that bladder activity can be changed more quickly and without the frequency of treatments related to PTNS.
Disclosed is a novel application for β-cyclodextrin (β-CD, a cholesterol depletor), and a novel technique for the creation of immunogens. Topical application of β-CD inhibits or reduces the severity of viral outbreaks such as oral or genital herpes by disrupting lipid rafts, through which viral entry and outbreak occur. Viral entry involves virus/lipid raft interaction, wherein the virus unfolds—only in lipid rafts—to enter the cell via the lipid raft. The invention provides a technique for creating immunogens with novel viral epitopes based on the virus/lipid raft interaction and viral unfolding. This fact can be exploited to create novel immunogens based on viral interaction with lipid rafts. The virus/lipid raft co-culture technique creates novel immunogens which will be used to create novel neutralizing monoclonal and polyclonal antibodies to fight viral disease such as HIV infection.
PURPOSE:A cosmetic, having a novelty in change of appearance without adversely affecting the body, and comprising phenolsulfonphthalein which is a diagnostic indicator used for renal function as a colorant for the cosmetic. CONSTITUTION:A skin cosmetic comprising phenolsulfonphthalein oxpressed by the formula [i.e. alpha-hydroxy-alpha, bis(p-hydroxy-phenyl)-o-toluenesulfonic acid]. The compound changes the color tone with pH, and as a colorant makes a cosmetic assume an orange to red color on keeping the pH of the base cosmetic at 7-8. The cosmetic turns yellow on application to the skin. EFFECT:Improved image of the product and increased buying interest.
This invention provides artificial viral envelopes and other lipid vesicles that encapsulate therapeutic substances, such as expression vectors, targeted to mammalian cells. Polynucleotides may be packed into the envelopes by compressing them beforehand with a short peptide with a predominant positive charge. The compression step not only facilitates encapsulation, it also increases the number of vesicles containing nucleic acid, minimizes the amount of free nucleic acid, and may also increase the size and complexity of plasmids that can be encapsulated. The vesicles may be provided with a tissue targeting component that helps direct it towards certain tissue sites in an animal. The vesicles may also be provided with a fusogenic component that facilitates delivery of the therapeutic substance into the cell. The materials and reagents of this invention are effective, for example, in increasing expression of model proteins in both isolated cells and intact animals, and are expected to be useful for gene therapy.
PURPOSE:To provide an external drung for topical application, having easily controllable viscosity and applicable without causing damage of the skin, by adding a specific amount of polyvinyl pyrrolidone to a topicum gel component composed of purified water containing the basis, an alcohol, a glycol, a carboxyvinyl polymer and a neutralizing agent. CONSTITUTION:The objective drug for external use is prepared by mixing purified water or alcohol containing the basis (e.g. camphor, menthol, steroid, etc.) with an aqueous or alcoholic solution of a carboxyvinyl polymer and polyvinyl pyrrolidone and adjusting the viscosity of the mixture to 2,000-7,000cp at room temperature (1-30 deg.C). The amount of polyvinyl pyrrolidone is 1-5wt%. When the basis is hardly soluble in water, the undesirable problems such as skin irritation, defatting of the skin, etc., caused by the use of a large amount of alcohol or glycol can be pevented by adding 1-10wt% of diethyl pyrocarbonate to the drug.
Authors are often faced with the decision of whether to maximize traditional impact metrics or minimize costs when choosing where to publish the results of their research. Many subscription-based journals now offer the option of paying an article processing charge (APC) to make their work open. Though such "hybrid" journals make research more accessible to readers, their APCs often come with high price tags and can exclude authors who lack the capacity to pay to make their research accessible. Here, we tested if paying to publish open access in a subscription-based journal benefited authors by conferring more citations relative to closed access articles. We identified 146,415 articles published in 152 hybrid journals in the field of biology from 2013-2018 to compare the number of citations between various types of open access and closed access articles. In a simple generalized linear model analysis of our full dataset, we found that publishing open access in hybrid journals that offer the option confers an average citation advantage to authors of 17.8 citations compared to closed access articles in similar journals. After taking into account the number of authors, Journal Citation Reports 2020 Quartile, year of publication, and Web of Science category, we still found that open access generated significantly more citations than closed access (p < 0.0001). However, results were complex, with exact differences in citation rates among access types impacted by these other variables. This citation advantage based on access type was even similar when comparing open and closed access articles published in the same issue of a journal (p < 0.0001). However, by examining articles where the authors paid an article processing charge, we found that cost itself was not predictive of citation rates (p = 0.14). Based on our findings of access type and other model parameters, we suggest that, in the case of the 152 journals we analyzed, paying for open access does confer a citation advantage. For authors with limited budgets, we recommend pursuing open access alternatives that do not require paying a fee as they still yielded more citations than closed access. For authors who are considering where to submit their next article, we offer additional suggestions on how to balance exposure via citations with publishing costs.
DSUVIA contains sufentanil, a Schedule II controlled substance. As an opioid, DSUVIA exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed DSUVIA. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient’s risk for opioid addiction, abuse, or misuse prior to prescribing DSUVIA, and monitor all patients receiving DSUVIA for the development of these behaviors or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as DSUVIA but use in such patients necessitates intensive counseling about the risks and proper use of DSUVIA along with intensive monitoring for signs of addiction, abuse, and misuse.

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing DSUVIA. Strategies to reduce these risks include proper product storage and control practices for a C-II drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
The present invention discloses a protective agent, hair dye and a method for resisting hypersensitiveness toward hair dye. The protective agent comprises plant drugs, such as licorice, baikal skullcap root and astragalus root, that are purified, and also comprises cucumisin, collencyte, phytohemagglutinin, potassium persulfate, sodium persulfate, tretinoin, etc. The hair dye of the present invention comprises p-phenylenediamine hair dye and protective agent. The present invention which can reduce and prevent sensitization and absorption poisoning during hair dyeing provides clinicians with effective measures for treating sensitizing dermatitis of p-phenylenediamine, enables the pathogenetic conditions of patients with allergic contact dermatitis caused by hair dye to be obviously alleviated so as to shorten the course of treatment, and avoids or reduces anaphylactic reaction for hair dyeing sensitive persons during or after hair dyeing. The hair dye containing protective agents can obviously shorten the time of hair dyeing and ensure the natural effect after hair dyeing. The present invention has the advantages of safety, convenient use and reliable effect, and can be used for shampoo, matched hair-dyeing boxes, external preparations for treating hair-dyeing sensitization, anti-anaphylaxis skin and hair, wig dye, etc.
The method is used in the pharmaceutical industry for the production of rifabutin which is the semi-synthetic derivative of rifamycin S, demonstrating expressed antibacterial activity. The process occurs at high yield, in a two-stage synthesis by means of bromation of rifamycin S with 1.1-1.5 mol/mol N-bromsucccinamide in a medium of dimethylformamide, containing more than 1 mol/mol dialkylamide at 4-6 degrees C and intensive agitation. Without isolation of he 3-bromrifamycin S produced, sodium nitrite is added to the reaction medium. Nitration occurs at temperature ranging for 0 to 10 degrees C at continuous agitation. The 3-nitrorifamycin S produced is reduced by means of zinc powder in the presence of acetic acid and urea and the 3-aminorifamycin SV is oxidized by means of manganese dioxide to 3-aminorifamycin S, which is isolated, re-crystallized and is treated by means of known methods until the production of rifabutin. 2 claims
The invention discloses a novel application of the extract of Rheum emodi Wall., and more specifically discloses an application of the extract of Rheum emodi Wall. in preparing anti-fibrosis drugs. According to results of animal experiments, the extract of Rheum emodi Wall. prepared by ethanol percolation and extraction and ethanol elution, especially 3,5,3',4'-tetrahydroxystilbene-4'-O-beta-D-glucopyranoside (PDG) in the extract, can inhibit the expression of transforming growth factor-beta 1 and the expression of TIMP-1 and promote the expression of Caspase-3 in fibrotic tissue, thereby reducing the generation and deposition of extracellular matrix (ECM) and substantially alleviating fibrosis of tissue. In the controlling of hepatic fibrosis, PDG can inhibit the activation and propagation of hepatic stellate cells (HSC) and induce the apoptosis of HSCs; as a whole, PDG has a substantial retroconversion effect on hepatic fibrosis of rats. Therefore, the extract of Rheum emodi Wall. or medical combinations containing the extract of Rheum emodi Wall. can be used for the preparation of anti-fibrosis drugs.
Described herein is a method of loading hydrophilic compounds into liposomes after addition of an alkyl ester group to form an esterified compound. After the loading, the carbalkoxy group is hydrolyzed to form a hydrophilic compound again inside the liposome. Also described herein is a method of loading a drug in the form of methyl glucuronide into liposomes. Inside the liposomes, the methyl glucuronide form of the drug is saponified to the glucuronide form of the drug to preferentially preserve the drug. After cellular absorption, lipid breakdown and enzymatic hydrolysis, the glucuronide residues bound to the drug can be removed from the cell to regenerate the parent drug. In the case of cancer, this method can be used to deliver drugs safely to tumors.
Provided herein is an ophthalmic composition, comprising an aqueous solution, comprising (i) a pharmaceutically effective amount of a phosphorylcholine-tuftsin conjugate, (ii) between 0.1 and 5% weight per weight (w/w) of a viscosity enhancer, and (iii) between 0.1 and 5% w/w of a mucoadhesive polymer. Provided herein is a synergistic preservative composition comprising a phosphorylcholine-tuftsin conjugate and BAK. Furthermore, a pharmaceutical composition (e.g. ophthalmic composition) comprising an effective amount of the preservative composition is also povided. A method of using the ophthalmic composition such as for treating or preventing ocular inflammation in a subject in need thereof is also provided. Furthermore, method of using the ophthalmic composition such as for enhancing ocular bioavailability of a phosphorylcholine-tuftsin conjugate within a subject is also provided.
PURPOSE: To stably produce the oxide sol of the single component or multicomponents of metals by hydrolyzing a specific aq. metal salt soln. or an aq. soln. of a metal salt mixture by direct electrolysis at a specific temp.  
     CONSTITUTION: The metal oxide sol of the single component or multicomponent system having a grain size of 5 to 1000 nm is stably produced by adjusting the concn. of the metal salts in the independent aq. soln. of salts of metals, such as Al, Ti, Zr, Hf, Nb, Ta, Y and La, or the salts of actinoids elements or salts of lanthanoids elements or an aq. soln. mixture composed of ≥2 kinds thereof to 0.5 to 40 wt.% and executing the electrolysis under electrical conditions of voltage of 2 to 20 V, current density of 0.01 to 0.5 A/cm 2 , etc., using grid-like electrodes made of Ti coated with ruthenium oxide and iridium oxide at an aq. soln. temp. of a wide temp. range of -10 to 50°C, then hydrolizing. 
     COPYRIGHT: (C)1993,JPO
The clinic application of doxorubicin (DOX) is severely limited by its severe cardiotoxicity. Tripartite motif-containing protein 16 (TRIM16) has E3 ubiquitin ligase activity and is upregulated in cardiomyocytes under pathological stress, yet its role in DOX-induced cardiotoxicity remains elusive. This study aims to investigate the role and mechanism of TRIM16 in DOX cardiotoxicity. Following TRIM16 overexpression in hearts with AAV9-TRIM16, mice were intravenously administered DOX at a dose of 4 mg/kg/week for 4 weeks to assess the impact of TRIM16 on doxorubicin-induced cardiotoxicity. Transfection of OE-TRIM16 plasmids and siRNA-TRIM16 was performed in neonatal rat cardiomyocytes (NRCMs). Our results revealed that DOX challenge elicited a significant upregulation of TRIM16 proteins in cardiomyocytes. TRIM16 overexpression efficiently ameliorated cardiac function while suppressing inflammation, ROS generation, apoptosis and fibrosis provoked by DOX in the myocardium. TRIM16 knockdown exacerbated these alterations caused by DOX in NRCMs. Mechanistically, OE-TRIM16 augmented the ubiquitination and degradation of p-TAK1, thereby arresting JNK and p38MAPK activation evoked by DOX in cardiomyocytes. Furthermore, DOX enhanced the interaction between p-TAK1 and YAP1 proteins, resulting in a reduction in YAP and Nrf2 proteins in cardiomyocytes. OE-TRIM16 elevated YAP levels and facilitated its nuclear translocation, thereby promoting Nrf2 expression and mitigating oxidative stress and inflammation. This effect was nullified by siTRIM16 or TAK1 inhibitor Takinib. Collectively, the current study elaborates that upregulating TRIM16 mitigates DOX-induced cardiotoxicity through anti-inflammation and anti-oxidative stress by modulating TAK1-mediated p38 and JNK as well as YAP/Nrf2 pathways, and targeting TRIM16 may provide a novel strategy to treat DOX-induced cardiotoxicity.
PROBLEM TO BE SOLVED: To obtain a nonfoaming gel shaving composition which is useful in shaving mustache, unwanted hairs and the like with a safety shaver or a razor by using a combination of a carboxyvinyl polymer and a polysaccharide polymer as a gelling agent and setting the viscosity of the composition in a specific range. SOLUTION: A carboxyvinyl polymer (preferably in an amount of 0.01-5.0wt.%), a polysaccharide polymer (preferably in an amount of 0.01-4.0wt.%) and water (in a balancing amount) are mixed and its Brookfield viscosity is adjusted to 10,000-70,000 centipoise at 30 deg.C. The polysaccharide polymer is preferably at least one selected from the group consisting hydroxyethylcellulose, hydroxypropylcellulose and carageenan. In addition, 0.1-5.0wt.% of a polyhydric alcohol and 0.01-1.0wt.% of a high polymer of polyethylene oxide with a molecular weight of >=100,000 may be admixed. Further, 0.1-50wt.% of an oil-in-water type emulsion may be added. Particularly, this composition preferably does not contain soap.
The present invention relates to a heart-nourishing tea capsule and a preparing method thereof. The preparing method is characterized in that 0.5 to 10 parts of American ginseng is pulverized into fine granules; water or alcohol in any proportion with the water is used as a solvent, five times of extracting are carried out at a back flow temperature, and each time lasts for two hours; the thin-layer chromatography is used for controlling an extracting end point; extracted liquid is merged, refrigerated and filtrated, and the filtrated liquid is concentrated into a thick paste form; pure water is added for uniform mix, refrigeration, filtration and standby; 2 to 30 parts of red sage root, 0.5 to 10 parts of liquorice root and 2 to 30 parts of achyranthes root are cut into slices to be mixed with 1 to 20 parts of lilyturf root and 0.5 to 10 parts of schisandra; the mixture is decocted for three times by adding water, the first time lasts for two hours, and the second time and the third time respectively last for 1 hour for decoction. Decocted liquid is merged and filtrated, and the pH value of the filtered liquid is adjusted to be 5 to 8. The decocted liquid is merged with the spare liquid of the American ginseng, and is eluted by the pure water until the effluent liquid is close to be colorless by a processed adsorbing column of macroporous resin. Then the ethanol is used for elution until the effluent liquid is close to be colorless, and the alcohol eluent is collected. The recovered solvent is distillated by pressure reduction, and is concentrated into the thick paste form. The recovered solvent in the thick paste form is dried in vacuum, ground, granulated and filled into capsules.